JP2004513626A5 - - Google Patents

Download PDF

Info

Publication number
JP2004513626A5
JP2004513626A5 JP2002526886A JP2002526886A JP2004513626A5 JP 2004513626 A5 JP2004513626 A5 JP 2004513626A5 JP 2002526886 A JP2002526886 A JP 2002526886A JP 2002526886 A JP2002526886 A JP 2002526886A JP 2004513626 A5 JP2004513626 A5 JP 2004513626A5
Authority
JP
Japan
Prior art keywords
compound
clusterin
disease
antisense oligonucleotide
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2002526886A
Other languages
English (en)
Japanese (ja)
Other versions
JP4397585B2 (ja
JP2004513626A (ja
Filing date
Publication date
Priority claimed from US09/659,791 external-priority patent/US6383808B1/en
Application filed filed Critical
Publication of JP2004513626A publication Critical patent/JP2004513626A/ja
Publication of JP2004513626A5 publication Critical patent/JP2004513626A5/ja
Application granted granted Critical
Publication of JP4397585B2 publication Critical patent/JP4397585B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2002526886A 2000-09-11 2001-09-10 クラスタリン発現のアンチセンスモジュレーション Expired - Fee Related JP4397585B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/659,791 US6383808B1 (en) 2000-09-11 2000-09-11 Antisense inhibition of clusterin expression
PCT/US2001/028235 WO2002022635A1 (en) 2000-09-11 2001-09-10 Antisense modulation of clusterin expression

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009191924A Division JP2010043086A (ja) 2000-09-11 2009-08-21 クラスタリン発現のアンチセンスモジュレーション

Publications (3)

Publication Number Publication Date
JP2004513626A JP2004513626A (ja) 2004-05-13
JP2004513626A5 true JP2004513626A5 (enExample) 2005-03-17
JP4397585B2 JP4397585B2 (ja) 2010-01-13

Family

ID=24646855

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2002526886A Expired - Fee Related JP4397585B2 (ja) 2000-09-11 2001-09-10 クラスタリン発現のアンチセンスモジュレーション
JP2009191924A Pending JP2010043086A (ja) 2000-09-11 2009-08-21 クラスタリン発現のアンチセンスモジュレーション
JP2013156811A Pending JP2014027936A (ja) 2000-09-11 2013-07-29 クラスタリン発現のアンチセンスモジュレーション

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2009191924A Pending JP2010043086A (ja) 2000-09-11 2009-08-21 クラスタリン発現のアンチセンスモジュレーション
JP2013156811A Pending JP2014027936A (ja) 2000-09-11 2013-07-29 クラスタリン発現のアンチセンスモジュレーション

Country Status (7)

Country Link
US (2) US6383808B1 (enExample)
EP (1) EP1325019B1 (enExample)
JP (3) JP4397585B2 (enExample)
AT (1) ATE496127T1 (enExample)
AU (1) AU2001290706A1 (enExample)
DE (1) DE60143901D1 (enExample)
WO (1) WO2002022635A1 (enExample)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040121973A1 (en) * 2002-02-05 2004-06-24 Monia Brett P Antisense modulation of protein phosphatase 2 Catalytic subunit alpha expression
US6444650B1 (en) * 1996-10-01 2002-09-03 Geron Corporation Antisense compositions for detecting and inhibiting telomerase reverse transcriptase
NZ513757A (en) 1999-02-26 2004-12-24 Univ British Columbia Antisense oligonucleotides to inhibit TRPM-2 expression and delay androgen independance in prostatic tumour cells
US6900187B2 (en) * 1999-02-26 2005-05-31 The University Of British Columbia TRPM-2 antisense therapy using an oligonucleotide having 2′-O-(2-methoxy)ethyl modifications
US7569551B2 (en) 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
US7199102B2 (en) 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
US7723303B2 (en) * 2000-08-24 2010-05-25 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
US7148197B2 (en) * 2000-08-24 2006-12-12 The Regents Of The University Of California Orally administered small peptides synergize statin activity
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
US7407943B2 (en) * 2001-08-01 2008-08-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein B expression
DK1465995T3 (da) * 2002-01-17 2008-10-20 Univ British Columbia Bispespecifikke antisense-olignukleotider der inhiberer IGFBP-2 og IGFBP og fremgangsmåder til anvendelse deraf
US20040102401A1 (en) * 2002-11-22 2004-05-27 Isis Pharmaceuticals Inc. Modulation of jagged 1 expression
WO2004003201A2 (en) * 2002-07-01 2004-01-08 Pharmacia Corporation Antisense modulation of lrh1 expression
KR101212512B1 (ko) * 2002-08-21 2012-12-26 더 유니버시티 오브 브리티쉬 콜롬비아 암-관련 단백질을 표적으로 하는 알엔에이아이 프로브
US7285541B2 (en) * 2002-08-21 2007-10-23 The University Of British Columbia Treatment of melanoma by reduction in clusterin levels
WO2004092379A2 (en) * 2003-04-18 2004-10-28 The University Of British Columbia Method for treatment of angiogenic disorders
US20040220131A1 (en) * 2003-04-18 2004-11-04 The University Of British Columbia Method for treatment of cancerous angiogenic disorders
US7825235B2 (en) * 2003-08-18 2010-11-02 Isis Pharmaceuticals, Inc. Modulation of diacylglycerol acyltransferase 2 expression
EP2363480A3 (en) * 2004-01-20 2015-10-07 Isis Pharmaceuticals, Inc. Modulation of glucocorticoid receptor expression
EP1708730A2 (en) * 2004-01-20 2006-10-11 DeveloGen Aktiengesellschaft Use of a dg147 protein product for preventing and treating metabolic disorders
US8710020B2 (en) * 2004-04-02 2014-04-29 The University Of British Columbia Clusterin antisense therapy for treatment of cancer
US20060205669A1 (en) * 2004-09-16 2006-09-14 The Regents Of The University Of California G-type peptides and other agents to ameliorate atherosclerosis and other pathologies
ITBZ20040048A1 (it) * 2004-10-06 2005-01-06 Genprofiler Metodo per l'identificazione della trasformazione neoplastica, con particolare riferimento al cancro prostatico
PT1814595E (pt) * 2004-11-23 2014-04-02 Univ British Columbia Tratamento de cancro com uma combinação de um agente que perturba a via de sinalização egf e um oligonucleótido que reduz os níveis de clusterina
US7579319B2 (en) 2004-12-06 2009-08-25 The Regents Of The University Of California Methods for improving the structure and function of arterioles
US20080293639A1 (en) * 2005-04-29 2008-11-27 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
JP2008539235A (ja) * 2005-04-29 2008-11-13 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 炎症反応によって特徴付けられる病状を処置するためのペプチドおよびペプチド模倣物
ES2543341T3 (es) 2005-09-13 2015-08-18 National Research Council Of Canada Métodos y composiciones para modular la actividad de células tumorales
RU2559536C2 (ru) 2007-03-24 2015-08-10 Джензим Корпорейшн Введение антисмысловых олигонуклеотидов, комплементарных человеческому аполипопротеину в
CA2697957A1 (en) 2007-08-28 2009-03-12 Uab Research Foundation Synthetic apolipoprotein e mimicking polypeptides and methods of use
JP2010538005A (ja) 2007-08-28 2010-12-09 ユーエービー リサーチ ファウンデーション 合成アポリポ蛋白質ｅ模倣ポリペプチドおよび使用方法
EP2222851B1 (en) * 2007-11-20 2017-06-28 Ionis Pharmaceuticals, Inc. Modulation of cd40 expression
ES2616051T3 (es) 2008-12-02 2017-06-09 Wave Life Sciences Japan, Inc. Método para la síntesis de ácidos nucleicos modificados en el átomo de fósforo
CA2767253A1 (en) 2009-07-06 2011-01-13 Ontorii, Inc. Novel nucleic acid prodrugs and methods of use thereof
CA2928846A1 (en) 2009-11-24 2011-06-03 Alethia Biotherapeutics Inc. Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume
EP2620428B1 (en) 2010-09-24 2019-05-22 Wave Life Sciences Ltd. Asymmetric auxiliary group
MX2013008944A (es) 2011-02-03 2014-01-08 Mirna Therapeutics Inc Mimeticos sinteticos de mir-124.
KR20140020900A (ko) 2011-02-03 2014-02-19 미르나 테라퓨틱스 인코포레이티드 Ｍｉｒ―34의 합성 모방체
KR20140038388A (ko) 2011-03-15 2014-03-28 더 유니버시티 오브 브리티쉬 콜롬비아 전립선암의 치료를 위한 항-클러스테린 올리고뉴클레오타이드와 hsp90 저해제의 병용
JP6128529B2 (ja) 2011-07-19 2017-05-17 ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． 官能化核酸の合成のための方法
US9580708B2 (en) 2011-09-14 2017-02-28 Rana Therapeutics, Inc. Multimeric oligonucleotides compounds
WO2013123588A1 (en) 2012-02-22 2013-08-29 Alethia Biotherapeutics Inc. Co-use of a clusterin inhibitor with an egfr inhibitor to treat cancer
US10837014B2 (en) 2012-05-16 2020-11-17 Translate Bio Ma, Inc. Compositions and methods for modulating SMN gene family expression
AU2013262709A1 (en) 2012-05-16 2015-01-22 Rana Therapeutics, Inc. Compositions and methods for modulating MECP2 expression
US9982257B2 (en) 2012-07-13 2018-05-29 Wave Life Sciences Ltd. Chiral control
MX356830B (es) 2012-07-13 2018-06-15 Shin Nippon Biomedical Laboratories Ltd Adyuvante de acido nucleico quiral.
US9598458B2 (en) 2012-07-13 2017-03-21 Wave Life Sciences Japan, Inc. Asymmetric auxiliary group
AU2013315225B2 (en) 2012-09-14 2018-11-08 Translate Bio Ma, Inc. Multimeric oligonucleotide compounds
EP3095459A4 (en) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having antitumor effect and antitumor agent
WO2015108046A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤
US10144933B2 (en) 2014-01-15 2018-12-04 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
DK3094728T3 (da) 2014-01-16 2022-05-16 Wave Life Sciences Ltd Kiralt design
BR112017001860A2 (pt) 2014-07-31 2018-02-27 Uab Research Foundation peptídeo sintético, composição farmacêutica, métodos, regime de dosagem, e, anticorpo monoclonal
AU2016219052B2 (en) * 2015-02-13 2022-06-02 Translate Bio Ma, Inc. Compositions and methods for modulating RNA
US10758558B2 (en) 2015-02-13 2020-09-01 Translate Bio Ma, Inc. Hybrid oligonucleotides and uses thereof
EP3294880A4 (en) * 2015-05-15 2018-12-26 Dharmacon, Inc. Synthetic single guide rna for cas9-mediated gene editing
DK3320094T3 (da) 2015-07-10 2022-05-23 Ionis Pharmaceuticals Inc Modulatorer af diacyglycerol-acyltransferase 2 (dgat2)
FR3069156B1 (fr) * 2017-07-21 2019-08-09 Universite de Bordeaux Clusterine pour son utilisation dans le traitement des micro-angiopathies thrombotiques

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US5405938A (en) 1989-12-20 1995-04-11 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5235033A (en) 1985-03-15 1993-08-10 Anti-Gene Development Group Alpha-morpholino ribonucleoside derivatives and polymers thereof
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US5216141A (en) 1988-06-06 1993-06-01 Benner Steven A Oligonucleotide analogs containing sulfur linkages
US5264564A (en) 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
US5264562A (en) 1989-10-24 1993-11-23 Gilead Sciences, Inc. Oligonucleotide analogs with novel linkages
US5470967A (en) 1990-04-10 1995-11-28 The Dupont Merck Pharmaceutical Company Oligonucleotide analogs with sulfamate linkages
US5610289A (en) 1990-07-27 1997-03-11 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogues
US5489677A (en) 1990-07-27 1996-02-06 Isis Pharmaceuticals, Inc. Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms
US5541307A (en) 1990-07-27 1996-07-30 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs and solid phase synthesis thereof
US5602240A (en) 1990-07-27 1997-02-11 Ciba Geigy Ag. Backbone modified oligonucleotide analogs
US5214134A (en) 1990-09-12 1993-05-25 Sterling Winthrop Inc. Process of linking nucleosides with a siloxane bridge
US5561225A (en) 1990-09-19 1996-10-01 Southern Research Institute Polynucleotide analogs containing sulfonate and sulfonamide internucleoside linkages
US5596086A (en) 1990-09-20 1997-01-21 Gilead Sciences, Inc. Modified internucleoside linkages having one nitrogen and two carbon atoms
FR2692265B1 (fr) 1992-05-25 1996-11-08 Centre Nat Rech Scient Composes biologiquement actifs de type phosphotriesters.
US5434257A (en) 1992-06-01 1995-07-18 Gilead Sciences, Inc. Binding compentent oligomers containing unsaturated 3',5' and 2',5' linkages
GB9304618D0 (en) 1993-03-06 1993-04-21 Ciba Geigy Ag Chemical compounds
FR2705099B1 (fr) 1993-05-12 1995-08-04 Centre Nat Rech Scient Oligonucléotides phosphorothioates triesters et procédé de préparation.
US5801154A (en) * 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
AUPM301293A0 (en) 1993-12-17 1994-01-20 University Of Melbourne, The Methods and reagents for sperm analysis
US5695995A (en) * 1994-05-06 1997-12-09 Fred Hutchinson Cancer Research Center Neurogenic differentiation (neurod) genes
US5786213A (en) * 1996-04-18 1998-07-28 Board Of Regents, The University Of Texas System Inhibition of endogenous gastrin expression for treatment of colorectal cancer
US5739310A (en) * 1996-04-23 1998-04-14 Fred Hutchinson Cancer Research Center Ribosomes as vectors for RNA
US5945290A (en) * 1998-09-18 1999-08-31 Isis Pharmaceuticals, Inc. Antisense modulation of RhoA expression
US5959097A (en) * 1998-11-20 1999-09-28 Isis Pharmaceuticals, Inc. Antisense modulation of MEK2 expression
US6464975B2 (en) * 1998-12-11 2002-10-15 The Research Foundation Of State University Of New York Compositions and methods for altering cell migration
US5958773A (en) * 1998-12-17 1999-09-28 Isis Pharmaceuticals Inc. Antisense modulation of AKT-1 expression
US5948680A (en) * 1998-12-17 1999-09-07 Isis Pharmaceuticals Inc. Antisense inhibition of Elk-1 expression
NZ513757A (en) 1999-02-26 2004-12-24 Univ British Columbia Antisense oligonucleotides to inhibit TRPM-2 expression and delay androgen independance in prostatic tumour cells
US5998148A (en) * 1999-04-08 1999-12-07 Isis Pharmaceuticals Inc. Antisense modulation of microtubule-associated protein 4 expression

Similar Documents

Publication Publication Date Title
JP2004513626A5 (enExample)
JP2004509619A5 (enExample)
CA2397590A1 (en) Antisense inhibition of ptp1b expression
JP2003523739A5 (enExample)
JP2005520489A5 (enExample)
JP2005503142A5 (enExample)
US20230020192A1 (en) Compounds and methods for modulating c90rf72
CA2451643A1 (en) Antisense modulation of superoxide dismutase 1, soluble expression
JP2018150344A5 (enExample)
TWI880645B (zh) 抑制lpa之基因表現之組合物及方法
CA2343102A1 (en) Antisense modulation of survivin expression
JP2009508527A5 (enExample)
JP2016530882A5 (enExample)
JP2010505432A5 (enExample)
JP2012050438A5 (enExample)
JP2021507686A5 (enExample)
JP2019534009A5 (enExample)
TW202307207A (zh) 用於抑制黃嘌呤脫氫酶(XDH)之表現之RNAi藥劑、其醫藥組合物及使用方法
JP2015502365A5 (enExample)
JP2005504522A5 (enExample)
JP2010500023A (ja) Ｄｎａリピートの不安定性に関連した遺伝的障害を治療するための方法及び手段
CN101980726A (zh) 治疗与dna重复不稳定性相关的遗传病症的方法和装置
JP2004503232A5 (enExample)
JP2006141402A5 (enExample)
RU2016115782A (ru) Лечение заболеваний, связанных с субстратом рецептора инсулина 2 (irs2), путем ингибирования природного антисмыслового транскрипта к irs2 и транскрипционному фактору е3 (tfe3)